• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ALK 重排型肺癌伴硬脊膜外髓内脊髓转移，克唑替尼治疗后有效：病例报告。

ALK-rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report.

机构信息

Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

出版信息

Thorac Cancer. 2018 Aug;9(8):1078-1081. doi: 10.1111/1759-7714.12778. Epub 2018 Jun 4.

DOI:10.1111/1759-7714.12778
PMID:29862659
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6068429/
Abstract

Intradural extramedullary spinal cord metastases in lung cancer are rarely reported, but are a disastrous event because of severe clinical symptoms and poor prognosis. Herein, we report a case of a lung cancer patient with ALK rearrangement who experienced brain, leptomeningeal, and intradural extramedullary spinal cord metastases after developing resistance to crizotinib. After ceritinib therapy, his clinical symptoms improved and magnetic resonance imaging revealed that the intradural extramedullary lesions had reduced.

摘要

肺癌脊髓硬膜外髓内转移罕见，但由于严重的临床症状和预后不良，仍是灾难性事件。在此，我们报告一例 ALK 重排的肺癌患者，在对克唑替尼耐药后发生脑、软脑膜和脊髓硬膜外髓内转移。接受塞瑞替尼治疗后，其临床症状改善，磁共振成像显示硬膜外病变缩小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8474/6068429/0b55666663b9/TCA-9-1078-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8474/6068429/20352d208414/TCA-9-1078-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8474/6068429/4df24f36f4bc/TCA-9-1078-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8474/6068429/0b55666663b9/TCA-9-1078-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8474/6068429/20352d208414/TCA-9-1078-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8474/6068429/4df24f36f4bc/TCA-9-1078-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8474/6068429/0b55666663b9/TCA-9-1078-g002.jpg

相似文献

1
ALK-rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report.ALK 重排型肺癌伴硬脊膜外髓内脊髓转移，克唑替尼治疗后有效：病例报告。
Thorac Cancer. 2018 Aug;9(8):1078-1081. doi: 10.1111/1759-7714.12778. Epub 2018 Jun 4.
2
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.ALK抑制剂治疗非小细胞肺癌脊柱转移的完全缓解
Neurology. 2019 Jul 30;93(5):217-219. doi: 10.1212/WNL.0000000000007866. Epub 2019 Jun 27.
3
Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.与脑放疗相比，脉冲剂量克唑替尼和色瑞替尼对ALK阳性非小细胞肺癌的持久脑反应。
J Clin Neurosci. 2016 Apr;26:46-9. doi: 10.1016/j.jocn.2015.05.068. Epub 2015 Dec 8.
4
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者的色瑞替尼治疗及不良事件管理
Lung Cancer. 2017 Sep;111:51-58. doi: 10.1016/j.lungcan.2017.06.004. Epub 2017 Jun 9.
5
Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review.口服 TKI 治疗：ALK 阳性 NSCLC 患者接受色瑞替尼治疗的疗效报告及文献复习
Curr Drug Targets. 2018;19(14):1649-1656. doi: 10.2174/1389450119666180213102939.
6
Clinical Efficacy of Alectinib in Patients with -Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.阿来替尼对色瑞替尼治疗失败的间变性淋巴瘤激酶重排非小细胞肺癌患者的临床疗效
Anticancer Res. 2017 Nov;37(11):6477-6480. doi: 10.21873/anticanres.12103.
7
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.色瑞替尼在间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌患者中的活性与安全性（ASCEND-1）：多中心、开放标签、1期试验的更新结果
Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11.
8
[Clinical Features of Intradural Extramedullary Spinal Cord Metastases 
in Primary Lung Cancer].[原发性肺癌硬脊膜内髓外脊髓转移的临床特征]
Zhongguo Fei Ai Za Zhi. 2016 Aug 20;19(8):539-44. doi: 10.3779/j.issn.1009-3419.2016.08.10.
9
Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase.色瑞替尼治疗间变性淋巴瘤激酶I1171T位点继发突变的癌性脑膜炎
Intern Med. 2018 Nov 1;57(21):3153-3155. doi: 10.2169/internalmedicine.0397-17. Epub 2018 Jun 6.
10
Organizing pneumonia in ALK+ lung adenocarcinoma treated with ceritinib: A case report and literature review.克唑替尼治疗后 ALK+肺腺癌合并机化性肺炎 1 例并文献复习
Medicine (Baltimore). 2021 Jul 2;100(26):e26449. doi: 10.1097/MD.0000000000026449.

引用本文的文献

1
A Case of Small-Cell Lung Cancer With Novel Anaplastic Lymphoma Kinase Gene Rearrangement That Developed Intradural Extramedullary Spinal Metastases With Myelitis.一例具有新型间变性淋巴瘤激酶基因重排的小细胞肺癌发生硬脊膜外髓外脊髓转移并伴有脊髓炎
Cureus. 2024 Dec 9;16(12):e75369. doi: 10.7759/cureus.75369. eCollection 2024 Dec.
2
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.间变性淋巴瘤激酶（ALK）和ROS1重排肺癌的转移方式、潜在机制及当前可能的治疗策略
RSC Adv. 2019 Jun 7;9(31):17921-17932. doi: 10.1039/c9ra02258a. eCollection 2019 Jun 4.

本文引用的文献

1
Leptomeningeal metastases in non-small-cell lung cancer.非小细胞肺癌的脑膜转移。
Lancet Oncol. 2018 Jan;19(1):e43-e55. doi: 10.1016/S1470-2045(17)30689-7.
2
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.欧洲神经肿瘤协会（EANO）与欧洲肿瘤内科学会（ESMO）关于实体瘤软脑膜转移患者诊断、治疗及随访的临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99. doi: 10.1093/annonc/mdx221.
3
[Clinical Features of Intradural Extramedullary Spinal Cord Metastases 
in Primary Lung Cancer].
[原发性肺癌硬脊膜内髓外脊髓转移的临床特征]
Zhongguo Fei Ai Za Zhi. 2016 Aug 20;19(8):539-44. doi: 10.3779/j.issn.1009-3419.2016.08.10.
4
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.针对 ALK 重排非小细胞肺癌的脑转移。
Lancet Oncol. 2015 Oct;16(13):e510-21. doi: 10.1016/S1470-2045(15)00013-3.
5
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.选择性ALK抑制剂阿来替尼在颅内转移模型中的抗肿瘤活性。
Cancer Chemother Pharmacol. 2014 Nov;74(5):1023-8. doi: 10.1007/s00280-014-2578-6. Epub 2014 Sep 10.
6
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.CH5424802，一种选择性的 ALK 抑制剂，能够阻断耐药性的守门员突变体。
Cancer Cell. 2011 May 17;19(5):679-90. doi: 10.1016/j.ccr.2011.04.004.
7
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.间变性淋巴瘤激酶抑制剂克唑替尼的脑脊液浓度。
J Clin Oncol. 2011 May 20;29(15):e443-5. doi: 10.1200/JCO.2010.34.1313. Epub 2011 Mar 21.
8
Leptomeningeal metastasis.脑膜转移。
Semin Neurol. 2010 Jul;30(3):236-44. doi: 10.1055/s-0030-1255220. Epub 2010 Jun 24.
9
Pathological examination of spinal lesions in meningeal carcinomatosis.脑膜癌病中脊髓病变的病理检查
Neuropathology. 2008 Jun;28(3):295-302. doi: 10.1111/j.1440-1789.2007.00879.x. Epub 2008 Jan 3.
10
Extramedullary intradural spinal tumors: a pictorial review.髓外硬膜内脊髓肿瘤：影像学综述
Curr Probl Diagn Radiol. 2007 Sep-Oct;36(5):185-98. doi: 10.1067/j.cpradiol.2006.12.002.